Rotavirus asisi

Rotavirus affects virtually all children during the first years of life in both developed and developing countries, and rotavirus infection is the one of the most common causes worldwide of severe gastroenteritis. Because of that, several rotavirus vaccines have been developed. One of these vaccines, an oral, live, tetravalent, rhesus-based rotavirus vaccine (RRV-TV) was found to be safe and effective in clinical trials among children and it is the only one now licensed for use among infants in the United States. The vaccine is an oral, live preparation that should be administered to infants between the ages of six weeks and one year. The recommended schedule is a three-dose series, with doses administered at ages two, four and six months. The first dose may be administered from the ages of six weeks to six months, and subsequent doses should be administered with a minimum interval of three weeks between any two doses. The first dose should not be administered to children aged seven months or older because of an increased rate of febrile reactions after the first dose among older infants. Furthermore, second and third doses should be administered before the first birthday. In this article we present recent information about the clinical presentation, the virus and the new vaccine. On postmarketing surveylance and vaccine advers events reporting system data, there seems to be increase risk intessusception after rotavirus vaccine, so Centers for Diseases Control and Prevention state to postpone rutine rotavirus vaccination on July 1999, and vaccine producing firm withdrawn their vaccine from market on November 1999.